Home > Healthcare > Pharmaceuticals > Finished Drug Form > Gabapentin Market

Gabapentin Market Size

Report ID: GMI6722
Published Date: Sep 2023
Report Format: PDF

Download Free Sample

Gabapentin Market Size

Gabapentin Market was estimated to be worth of USD 2 billion in 2022 and is projected to reach USD 3.2 billion by 2032, growing at a CAGR of 4.9% by 2032 due to the rising incidence of neuropathic pain, the growing off-label utilization of gabapentin, the broadening spectrum of gabapentin's applications, and the increasing recognition of gabapentin as an efficacious choice for pain management drug.

To get key market trends

Download Free Sample

Gabapentin is a medication mainly prescribed to treat specific types of neuropathic pain and as an anticonvulsant. It is a member of the gabapentinoids drug class. It works by impacting certain chemicals in the brain and nerves that are involved in the sensation of pain and seizures.

Gabapentin Market Report Attributes
Report Attribute	Details
Base Year:	2023
Gabapentin Market Size in 2023:	USD 2.1 Billion
Forecast Period:	2024 to 2032
Forecast Period 2024 to 2032 CAGR:	4.9%
2032 Value Projection:	USD 3.2 Billion
Historical Data for:	2018 to 2023
No. of Pages:	157
Tables, Charts & Figures:	278
Segments covered:	Type, Dosage Form, Application, Distribution Channel, and Region
Growth Drivers:	Increasing incidences of neuropathic pain Increasing off-label use of gabapentin Expanded indications of gabapentin Rising awareness of gabapentin as an effective treatment option for pain management Side effects associated with gabapentin
Pitfalls & Challenges:	Availability of alternative treatments Increasing misuse of gabapentin

Learn more about the key segments shaping this market

Download Free Sample

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Gabapentin market size was USD 2.1 billion in 2023 and will register 4.9% CAGR from 2024 -2032 due to the rising incidence of neuropathic pain worldwide.

The generic type segment held 79.3% share of the industry in 2022 and will incur significant growth from 2023-2032 on account of high affordability and cost effectiveness when compared to the branded counter parts.

North America industry recorded USD 786.3 million in revenue in 2022 and is expected to witness appreciable growth from 2023-2032 owing to the rising prevalence of epilepsy, and neuropathic pain along with the presence of key players in the region.

Pfizer Inc., Glenmark Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Ascend Laboratories, LLC, Apotex Inc., Teva Pharmaceutical Industries Ltd., and Aurobindo Pharma Ltd., are some of the major gabapentin companies worldwide.